- Home
- DSY vs NRXP Comparison
DSY vs NRXP Comparison
Compare DSY & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSY
- NRXP
- Stock Information
- Founded
- DSY 2020
- NRXP 2015
- Country
- DSY China
- NRXP United States
- Employees
- DSY N/A
- NRXP N/A
- Industry
- DSY
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- DSY
- NRXP Health Care
- Exchange
- DSY Nasdaq
- NRXP Nasdaq
- Market Cap
- DSY 72.0M
- NRXP 58.5M
- IPO Year
- DSY N/A
- NRXP N/A
- Fundamental
- Price
- DSY $1.07
- NRXP $2.32
- Analyst Decision
- DSY
- NRXP Strong Buy
- Analyst Count
- DSY 0
- NRXP 4
- Target Price
- DSY N/A
- NRXP $29.25
- AVG Volume (30 Days)
- DSY 10.3K
- NRXP 495.0K
- Earning Date
- DSY 01-01-0001
- NRXP 08-18-2025
- Dividend Yield
- DSY N/A
- NRXP N/A
- EPS Growth
- DSY 120.37
- NRXP N/A
- EPS
- DSY 0.01
- NRXP N/A
- Revenue
- DSY $7,323,356.00
- NRXP N/A
- Revenue This Year
- DSY N/A
- NRXP N/A
- Revenue Next Year
- DSY N/A
- NRXP $231.16
- P/E Ratio
- DSY $86.83
- NRXP N/A
- Revenue Growth
- DSY 16.37
- NRXP N/A
- 52 Week Low
- DSY $0.95
- NRXP $1.10
- 52 Week High
- DSY $6.98
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- DSY 38.83
- NRXP 37.39
- Support Level
- DSY $1.03
- NRXP $2.40
- Resistance Level
- DSY $1.10
- NRXP $2.83
- Average True Range (ATR)
- DSY 0.06
- NRXP 0.22
- MACD
- DSY 0.01
- NRXP -0.00
- Stochastic Oscillator
- DSY 37.44
- NRXP 8.70
About DSY Big Tree Cloud Holdings Limited Ordinary Shares
Big Tree Cloud Holdings Ltd is a consumer-oriented, mission-driven, and technology-empowered company engaged in the development, production, and sales of personal care products and other consumer goods. In particular, it is focused on the development and production of feminine pads and other feminine hygiene products. Through its platform, the company focuses on high-quality product development, deep customer engagement, and efficient sales and marketing.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.